India suspends import and manufacture of rosiglitazone and combinations
This article was originally published in Scrip
Executive Summary
India has suspended the importation and manufacture of the diabetes drug, rosiglitazone, following recent international regulatory action against the original branded version, GlaxoSmithKline's Avandia, and other rosiglitazone-containing products in view of the molecule's link to cardiovascular safety issues.